Get more info on this report!Emerging Cancer Vaccines: Market Forecasts, New Developments and...
•   Reviews of Products in the Pipeline           •   Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Ma...
Size and Growth of the Market    Issues and Trends Affecting Market    Leading CompetitorsCHAPTER TWO: INTRODUCTION    Int...
CHAPTER THREE: CERVICAL CANCER VACCINES    Overview    Description of Vaccines on the Market    Gardasil/Silgard    Cervar...
CDX-1307-01    Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine    MKC1106-PP    Market Summary    Po...
Description of Vaccines in Development    MyVax    BiovaxID    FavId    TG 1042    Market Summary    Potential Competitors...
Provenge    DCVax-Prostate    GVAX    ProstAtak    TroVAX    Telomerase Cancer Vaccine    MVA-BN Prostate    HyperAcute Pr...
GV 1001    GI-4000    Avicine    GVAX    HyperAcute Pancreas    Oncophage    CDX-1307-01    CRS-100    CRS-207    DC Vax  ...
CHAPTER TWELVE: BRAIN CANCER VACCINES    Overview    Glioblastoma    Neuroblastoma    Description of Vaccines in Developme...
Market SummaryCHAPTER FIFTEEN: LEUKEMIA VACCINES    Overview    Description of Vaccines in Development    GVAX    PR1 Pept...
Avax Technologies, Inc    Biovest International, Inc    Cell Genesys, Inc    Dendreon Corporation    Genitope Corporation ...
Sexes, 2004       •   Table 2-7: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both         ...
Revenues, Projected 2012       •   Figure 6-4: Anticipated Product Sales by Year for Emerging Lymphoma Vaccines, 2010-2012...
•   Figure 11-1: Estimated World Incidence of Renal Cancer by Country, 2007       •   Table 11-2: Renal Cancer Vaccines in...
and Vaccine Indication, 2012CANCER VACCINE CORPORATE PROFILESCOMPANY NAMES AND ADDRESSES       Available immediately for O...
Upcoming SlideShare
Loading in …5
×

Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition

923 views
887 views

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
923
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
9
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition

  1. 1.    Get more info on this report!Emerging Cancer Vaccines: Market Forecasts, New Developments and PipelineAnalysis, 3rd EditionNovember 1, 2008It is the general consensus of scientists that cancer vaccines will become a reality.Overall the cancer treatment market continues to grow and this demand sets the stagefor vaccine products.There are several promising vaccines: the propholactic Gardasil has created a pathwayfor new vaccine products. M-Vax, Ocon-Vax in late stage development and arepreparing for regulatory review in the United States, Europe, Canada, or otherinternational regions. Many of the products with potential approval status over thecoming years are already in Phase III development, have orphan drug status, SPAstatus, or Fast Track status. This provides a promising future for many of theseproducts. Additionally, some products in international regions have been grantedcompassionate use status which is significant in evaluating need on a patient-by-patientbasis. In this report, Kalorama Information provides a realistic estimate of the cancervaccine for the near term for the following products: • Melonoma Vaccines • Lung Cancer Vaccines • Prostate Cancer Vaccines • Cervical Cancer Vaccines • Brain Cancer Vaccines • Colon/Rectal Cancer Vaccines • Breast Cancer Vaccines • Lymphoma Vaccines • Ovarian Cancer Vaccines • Leukemia Vaccines • Bladder Cancer VaccinesAs part of its exhaustive research and analysis, this report provides: • Forecasts for Future Revenues from Cancer Vaccines • Cancer Epidemiology
  2. 2. • Reviews of Products in the Pipeline • Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Market • Directory of Related Companies Some of the issues discussed in this report important for anyone operating in this market include: • Introduction • Early Detection and Screening • Monoclonal Antibodies and Therapeutic Vaccines • Political and Social Pressure • Insurance and Reimbursement Issues • Personalized Medicine • Pharmacogenomics • Vaccine Strategies • New Genetic Technique • Future Growth in Vaccines As part of its detailed coverage of developments in cancer vaccines..the following companies are profiled in this report: • Antigenics, Inc. • Avax Technologies, Inc. • Biovest International, Inc. • Cell Genesys, Inc. • Dendreon Corporation • Genitope Corporation • GlaxoSmithKline plc • Merck & Company, Inc. • Northwest Biotherapeutics, Inc. • NovaRx • Oncothyreon • Vaccinogen • Vical, Inc. Table of ContentsCHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology
  3. 3. Size and Growth of the Market Issues and Trends Affecting Market Leading CompetitorsCHAPTER TWO: INTRODUCTION Introduction History and Growth of the Cancer Treatment Market Types of Vaccines Antigen/Adjuvant Vaccines Whole Cell Tumor Vaccines Dendritic Cell (DC) Vaccines Viral Vectors and DNA Vaccines Idiotype Vaccines Types of Therapeutic Vaccines Patient-Specific Vaccines Prostate Specific Antigen Sialyl Tn Heat Shock Proteins Ganglioside Molecules Carcinoembryonic Antigen (CEA) MART-1 Tyrosinase Adjuvants Industry Structure Demographics and Statistics Growing and Aging Population Life Expectancy and Cancer
  4. 4. CHAPTER THREE: CERVICAL CANCER VACCINES Overview Description of Vaccines on the Market Gardasil/Silgard Cervarix Description of Vaccines in Development TG 4001/R3484 HspE7 Lovaxin C VGX-3100 CA-9 Market Summary Current and Potential Competitors and Analysis, 2012CHAPTER FOUR: COLON/RECTAL CANCER VACCINES Overview Description of Vaccines on the Market OncoVAX Description of Vaccines in Development OncoVAX TroVAX Avicine CEA VRP Vaccine Collidem IMA910 Lapuleucel-T Oncophage
  5. 5. CDX-1307-01 Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine MKC1106-PP Market Summary Potential Competitors and Analysis, 2012CHAPTER FIVE: LUNG CANCER VACCINES Overview Description of Vaccines in Development Lucanix MAGE-A3 Peptide Stimuvax EGF Cancer Vaccine GV-1001 HyperAcute Lung IDM 2101 (EP-2101) Oncophage INGN 225 TG 4010 LungVAX Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine DC Vax L523S Market Summary Potential Competitors and Analysis, 2012CHAPTER SIX: LYMPHOMA VACCINES Overview
  6. 6. Description of Vaccines in Development MyVax BiovaxID FavId TG 1042 Market Summary Potential Competitors and Analysis, 2012CHAPTER SEVEN: MELANOMA VACCINES Overview Description of Vaccines on the Market Description of Vaccines in Development M-VAX GMK Allovectin-7 MDX-1379 with Combination Treatment MDX-010 Oncophage MAGE-A3 ASCI 3 Uvidem AGI-101H Vaccine ALVAC Vaccine HyperAcute Melanoma Market Summary Potential Competitors and Analysis, 2012CHAPTER EIGHT: PROSTATE CANCER VACCINES Overview Description of Vaccines in Development
  7. 7. Provenge DCVax-Prostate GVAX ProstAtak TroVAX Telomerase Cancer Vaccine MVA-BN Prostate HyperAcute Prostate MKC1106-PP Market Summary Potential Competitors and Analysis, 2012CHAPTER NINE: BREAST CANCER VACCINES Overview Description of Vaccines in Development INGN 225 CEA VRP Vaccine MVA-BN HER2 Lapuleucel-T PX 104.1 CDX-1307-02 Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine MKC1106-PP Market SummaryCHAPTER TEN: GASTROINTESTINAL CANCER VACCINES Overview Description of Vaccines in Development
  8. 8. GV 1001 GI-4000 Avicine GVAX HyperAcute Pancreas Oncophage CDX-1307-01 CRS-100 CRS-207 DC Vax MKC1106-PP Market SummaryCHAPTER ELEVEN: RENAL CANCER VACCINES Overview Description of Vaccines on the Market Oncophage Description of Vaccines in Development Oncophage Reniale TroVAX IMA901 AGS-003 MDX-1106 MKC1106-PP Market Summary Potential Competitors and Analysis, 2012
  9. 9. CHAPTER TWELVE: BRAIN CANCER VACCINES Overview Glioblastoma Neuroblastoma Description of Vaccines in Development DCVax-Brain CDX-110 GliAtak Oncophage Market SummaryCHAPTER THIRTEEN: BLADDER CANCER VACCINES Overview Description of Vaccines on the Market BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-Shire Pharmaceuticals) Description of Vaccines in Development Bexidem CG0070 MDX-1307-01 Market SummaryCHAPTER FOURTEEN: OVARIAN CANCER VACCINES Overview Description of Vaccines in Development OVax Autologous Cell Vaccine Lapuleucel-T Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine MKC1106-PP
  10. 10. Market SummaryCHAPTER FIFTEEN: LEUKEMIA VACCINES Overview Description of Vaccines in Development GVAX PR1 Peptide Vaccine AGS-005 Market SummaryCHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET Introduction Early Detection and Screening Monoclonal Antibodies and Therapeutic Vaccines Political and Social Pressure Insurance and Reimbursement Issues Personalized Medicine Pharmacogenomics Vaccine Strategies New Genetic Technique Future Growth in VaccinesCHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS Overview Total Market Size and Forecast Market and Competitor AnalysisCHAPTER EIGHTEEN: CANCER VACCINE CORPORATE PROFILES Introduction Antigenics, Inc
  11. 11. Avax Technologies, Inc Biovest International, Inc Cell Genesys, Inc Dendreon Corporation Genitope Corporation GlaxoSmithKline plc Merck & Company, Inc Northwest Biotherapeutics, Inc NovaRx Oncothyreon Vaccinogen Vical, IncCHAPTER NINETEEN: COMPANY NAMES AND ADDRESSES TABLE OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY • Table 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012 • Figure 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012CHAPTER TWO: INTRODUCTION • Table 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020 • Figure 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020 • Table 2-2: Total Cancer Incidence by Sex and Country, 2007 Estimates • Figure 2-2: Total Cancer Incidence by Sex and Country • Table 2-3: World Population by Selected Geographical Region, 2007-2050 • Figure 2-4: World Population by Selected Geographical Region, 2007-2050 • Table 2-4: Estimated World Population by Age and Geographical Region, 2007 • Figure 2-4: Estimated World Population by Age and Geographical Region, 2007 • Table 2-5: Percent Population Over 65 by Year and Region • Figure 2-5: Estimated World Population by Age, 2007 and 2050 • Table 2-6: Life Expectancy at Birth by Selected Countries, 2006 • Table 2-6: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both
  12. 12. Sexes, 2004 • Table 2-7: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004CHAPTER THREE: CERVICAL CANCER VACCINES • Table 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007 • Figure 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007 • Table 3-2: Cervical Cancer Vaccines Approved and in the Pipeline • Table 3-3: The Developing Cervical Cancer Vaccine Market, 2008-2012 • Figure 3-2: The Developing Cervical Cancer Vaccine Market, 2008-2012 • Table 3-4: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012 • Figure 3-3: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012 • Figure 3-4: Anticipated Product Sales by Year for Cervical Cancer Vaccines, 2008-2012CHAPTER FOUR: COLON/RECTAL CANCER VACCINES • Table 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007 • Figure 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007 • Table 4-2: Colon/Rectal Cancer Vaccines in the Pipeline • Table 4-3: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012 • Figure 4-2: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012 • Figure 4-3: Anticipated Product Sales by Year for Emerging Colon/Rectal Cancer Vaccines, 2008- 2012CHAPTER FIVE: LUNG CANCER VACCINES • Table 5-1: Types of Primary Lung Cancer • Table 5-2: Estimated World Incidence of Lung Cancer by Country, 2007 • Figure 5-1: Estimated World Incidence of Lung Cancer by Country, 2007 • Table 5-3: Lung Cancer Vaccines in the PipelineCHAPTER SIX: LYMPHOMA VACCINES • Table 6-1: Classification of Non-Hodgkin’s Lymphomas • Table 6-2: Estimated World Incidence of Lymphoma by Country, 2007 • Figure 6-1: Estimated World Incidence of Lymphoma by Country, 2007 • Table 6-3: Lymphoma Vaccines in the Pipeline • Table 6-4: The Emerging Lymphoma Vaccine Market, 2008-2012 • Figure 6-2: The Emerging Lymphoma Vaccine Market, 2008-2012 • Table 6-5: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012 • Figure 6-3: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market
  13. 13. Revenues, Projected 2012 • Figure 6-4: Anticipated Product Sales by Year for Emerging Lymphoma Vaccines, 2010-2012CHAPTER SEVEN: MELANOMA VACCINES • Table 7-1: Malignant Condidtions of the Skin • Table 7-2: Estimated World Incidence of Melanoma by Country, 2007 • Figure 7-1: Estimated World Incidence of Melanoma by Country, 2007 • Table 7-3: Melanoma Vaccines in the Pipeline • Table 7-4: The Developing Melanoma Vaccine Market, 2008-2012 • Figure 7-2: The Developing Melanoma Vaccine Market, 2008-2012 • Table 7-5: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012 • Figure 7-3: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012 • Figure 7-4:Anticipated Product Sales by Year for Developing Melanoma Vaccines, 2010-2012CHAPTER EIGHT: PROSTATE CANCER VACCINES • Table 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007 • Figure 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007 • Table 8-2: Prostate Cancer Vaccines in the Pipeline • Table 8-3: The Emerging Prostate Cancer Vaccine Market, 2008-2012 • Figure 8-2: The Emerging Prostate Cancer Vaccine Market, 2008-2012 • Table 8-4: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012 • Figure 8-3: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012 • Figure 8-4: Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2012CHAPTER NINE: BREAST CANCER VACCINES • Table 9-1: Estimated World Incidence of Breast Cancer by Country, 2007 • Figure 9-1: Estimated World Incidence of Breast Cancer by Country, 2007 • Table 9-2: Breast Cancer Vaccines in the PipelineCHAPTER TEN: GASTROINTESTINAL CANCER VACCINES • Table 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007 • Figure 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007 • Table 10-2: Gastrointestinal Cancer Vaccines in the PipelineCHAPTER ELEVEN: RENAL CANCER VACCINES • Table 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
  14. 14. • Figure 11-1: Estimated World Incidence of Renal Cancer by Country, 2007 • Table 11-2: Renal Cancer Vaccines in the Pipeline • Table 11-3: The Developing Renal Cancer Vaccine Market, 2008-2012 • Figure 11-2: The Developing Renal Cancer Vaccine Market, 2008-2012 • Table 11-4: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012 • Figure 11-3: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012 • Figure 11-4: Anticipated Product Sales by Year for Renal Cancer Vaccines, 2008-2012CHAPTER TWELVE: BRAIN CANCER VACCINES • Table 12-1: Estimated World Incidence of Brain Cancer by Country, 2007 • Figure 12-1: Estimated World Incidence of Brain Cancer by Country, 2007 • Table 12-2: Brain Cancer Vaccines in the PipelineCHAPTER THIRTEEN: BLADDER CANCER VACCINES • Table 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007 • Figure 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007 • Table 13-2: Bladder Cancer Vaccines in the PipelineCHAPTER FOURTEEN: OVARIAN CANCER VACCINES • Table 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007 • Figure 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007 • Table 14-2: Ovarian Cancer Vaccines in the PipelineCHAPTER FIFETEEN: LEUKEMIA VACCINES • Table 15-1: TYPES OF LEUKEMIA • Table 15-2: Estimated World Incidence of Leukemia by Country, 2007 • Figure 15-1: Estimated World Incidence of Leukemia Cancer by Country, 2007 • Table 15-3: Leukemia Vaccines in the PipelineCHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET • Table 16-1: Cancer Detection TestsCHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS • Table 17-1: Cancer Vaccines: Developing and Emerging Cancer VaccineMarkets, 2008-2012 • Figure 17-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012 • Figure 17-2: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent
  15. 15. and Vaccine Indication, 2012CANCER VACCINE CORPORATE PROFILESCOMPANY NAMES AND ADDRESSES Available immediately for Online Download at http://www.marketresearch.com/product/display.asp?productid=1646591    US: 800.298.5699 UK +44.207.256.3920 Intl: +1.240.747.3093 Fax: 240.747.3004 

×